查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1198165

射频消融设备市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Radiofrequency Ablation Devices Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 110 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在 2022 年至 2027 年的研究期间，射频消融设备市场预计将以 10.4% 的复合年增长率显着增长。

COVID-19 大流行影响了世界各地的医疗保健系统，扰乱了许多医疗机构的正常护理，并使易受伤害的癌症患者面临重大风险。 例如，2020 年发布的“COVID-19 大流行对癌症治疗的影响：一项全球合作研究”包括 2020 年 4 月 21 日至 5 月 8 日期间参与的 6 大洲 54 个国家/地区。根据对 356 个设施的调查，一些挑战在提供癌症护理方面已有报导。 这些设施每年为 716,979 名新癌症患者提供服务。 大多数 (88.2%) 报告在大流行期间提供护理方面存在挑战。 作为先发製人战略的一部分，55.34% 的中心缩减了服务，其他常见原因是系统超载 (19.94%)、缺乏个人防护设备 (19.10%) 和工作人员不足 (17.98%)，以及药物获取受限(9.83%)。 此外，在 COVID-19 大流行高峰期间，房颤 (AF) 的导管消融手术显着缩减，以节省医疗资源并减少辐射暴露。 根据 2021 年 2 月发表的“在 COVID-19 大流行中重启心房颤动消融”研究，研究对像中没有因消融而感染 COVID-19 的病例。 然而，儘管 2020 年持续性心律失常的患病率很高，但与 2019 年相比，进行的经食管超声心动图检查较少，医疗资源被重新用于 COVID-19 护理。 结果，消融手术的数量减少，这对市场产生了负面影响。 因此，大流行的早期对市场增长率产生了重大影响。 然而，随着世界各地的一些选择性和癌症治疗已恢復到大流行前的水平，预计市场将获得更多牵引力。

推动市场增长的因素包括微创手术的普及、慢性病负担的增加以及老年人口的增加。 例如，根据 GLOBOCAN 2020 的 2020 年统计数据，2020 年有 19,292,789 人被诊断出患有癌症。 同样的数据估计，2040年癌症患者人数将达到3020万。 因此，癌症患病率的增加表明对有效的癌症微创手术的需求不断增长，从而推动了对射频消融设备的需求。

此外，产品发布、合併、收购和合作伙伴关係等战略举措将带来利润丰厚的市场增长。 例如，2022年3月，Shijiazhuang Speedin Instruments推出了射频信号发生器，这是一种专门用于载波测试的射频信号发生器。

此外，不断增加的研究和开发证明了市场上现有产品的功效，预计将进一步促进市场增长。 例如，2022 年 1 月发表的论文“下一代导管缩短 AF 消融时间”评估了 Biosense-Webster 的 Qdot Micro 导管，将温控消融与接触力的 3D 电解剖映射相结合。它已被证明是一种灵敏的射频消融导管。 该导管提供高能量消融、改进的温度监测、优化的冲洗和高信号分辨率，可帮助医生通过简单的工作流程缩短手术时间。 射频消融设备的这些优势有望增强其适应性，从而推动市场增长。 此外，2022 年 2 月，Ramesh 医院将在印度维杰亚瓦达开设一个现代化的心臟电生理学实验室，该实验室将采用射频消融、起搏器和自动植入式心律转復除颤器等新疗法。 预计此类举措将增加对高频治疗设备的需求并推动市场增长。

因此，由于上述因素，该研究涵盖的市场预计在研究期间将显着增长。 然而，替代疗法的低意识和可用性以及高昂的治疗成本预计将阻碍预测期内的市场增长。

高频消融设备市场趋势

市场细分预计在预测期内占最大份额

肿瘤科在高频消融设备市场占有很大份额。 全球范围内越来越多的癌症患者正在推动该细分市场的增长。 例如，2021 年 9 月世界卫生组织 (WHO) 的最新消息指出，癌症已在全球范围内夺去约 1000 万人的生命。 2020年最常见的癌症（根据新增癌症患者人数）依次为乳腺癌（226万）、肺癌（221万）、结直肠癌（193万）、前列腺癌（141万）、皮肤癌（非黑色素瘤）（1.2万）和胃（109 万）。 这种病例数的同比增长极大地促进了手术治疗的有效治疗，从而推动了对消融设备的需求。

此外，根据 2021 年 2 月更新的 RadiologyInfo.org 文章，射频消融 (RFA) 是一种微创癌症治疗方法，它使用图像引导技术加热来杀死癌细胞。它具有破坏性。 RFA利用超声波、CT（计算机断层扫描）、MRI（磁共振成像）等将针状电极引导至癌性肿瘤，通过电极，高频电流通过放置在其上的接地垫身体，它会产生集中的热量，破坏电极周围的癌细胞。 该文章还表明，射频和微波消融治疗是癌症治疗中最常用的方式。

此外，增加研发投入也将提高射频消融设备在治疗各类癌症方面的可用性，从而加速该细分市场的增长。 例如，杭州市第一人民医院于 2020 年发表了一项题为“内窥镜射频消融术 (RAF) 联合吉西他滨和 S-1 治疗无法切除的胆管癌患者：一项随机、开放标籤临床试验”的研究。该研究于 1 月开始2020年，将比较RAF联合吉西他滨和S-1治疗不可切除胆管癌的疗效和安全性。 该试验预计将于 2022 年 6 月完成。 因此，此类做法的良好结果将刺激这一领域的增长。

因此，预计研究部门在分析期间将实现有利增长。

北美占据了很大的市场份额，预计在预测期内也会如此

北美射频 (RF) 消融设备市场增长的主要驱动力是慢性病患病率的增加、微创手术需求的增加、产品发布的增加以及主要市场参与者的战略主动性的提高。 预计在预测期内，美国将占据北美地区研究市场的很大份额。 例如，据2022年美国癌症协会估计，2022年全国将诊断出约236,740例肺癌新病例。 该文件还指出，到 2022 年，将报告 79,000 例肾癌新病例和 13,920 例死亡病例。 因此，癌症的高负担有望增加对消融设备的需求，从而推动市场增长。

此外，主要市场参与者采取的战略举措（例如产品发布、合作伙伴关係、新计划、併购）预计将推动市场增长。 例如，2021 年 2 月，美国食品和药物管理局批准Medtronic的 DiamondTemp 冲洗消融导管用于治疗对射频心臟消融空间内的药物治疗无反应的复发性心房颤动患者。

此外，在 2020 年 11 月，Abbott推出了 IonicRF 发生器，该发生器有望提供一种非手术、微创治疗来治疗神经性疼痛。 IonicRF 发生器是一种射频消融设备，它使用热量来瞄准特定神经并阻止疼痛信号到达大脑。 因此，推出此类产品将扩大公司的产品供应和地理足迹，推动预测期内的市场增长。

因此，上述这些因素预计将在未来几年推动该地区市场的增长。

高频消融器械市场竞争者分析

市场由大公司主导，竞争温和。 主要参与者有 Avanos Medical Inc.、Stryker、Abbottt、Medtronic、Boston Scientific Corporation 等。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动力
    • 越来越喜欢微创手术
    • 慢性病患病率增加
  • 市场製约因素
    • 对替代疗法的认识和可用性较低
    • 高昂的治疗费用
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：100 万美元）

  • 按产品类型
    • 高频发生器
    • 消耗品
  • 通过申请
    • 肿瘤科
    • 心脏病学和心率管理
    • 妇科
    • 疼痛管理
    • 其他应用
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Avanos Medical, Inc.
    • Stryker
    • Abbottt
    • Medtronic
    • Boston Scientific Corporation
    • Becton, Dickinson and Company（Venclose, Inc.）
    • AngioDynamics, Inc.
    • Hologic, Inc.
    • AtriCure, Inc.
    • Koninklijke Philips N.V.
    • Smith+Nephew
    • Baylis Medical Company, Inc

第七章市场机会与未来趋势

简介目录
Product Code: 90538

The Radiofrequency Ablation Devices market is expected to grow at a significant CAGR of 10.4% during the study period, 2022-2027.

The COVID-19 pandemic affected healthcare systems globally and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cancer to significant risks. For instance, a study titled "Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study" published in 2020 reported that there were several challenges in delivering cancer care based on a survey of a total of 356 centers from 54 countries across six continents that participated between April 21 and May 8, 2020. These centers serve 716,979 new patients with cancer every year. Most of them (88.2%) reported facing challenges in delivering care during the pandemic. Although 55.34% of the centers reduced their services as part of a preemptive strategy, other common reasons included an overwhelmed system (19.94%), lack of personal protective equipment (19.10%), staff shortage (17.98%), and restricted access to medications (9.83%). Moreover, catheter ablation procedures for atrial fibrillation (AF) were significantly curtailed during the peak of the COVID-19 pandemic to conserve healthcare resources and limit exposure. According to the study "Rebooting atrial fibrillation ablation in the COVID-19 pandemic," published in February 2021, there were no cases of ablation-related COVID-19 transmission in the study population. However, there were a smaller number of transesophageal echocardiography procedures performed in 2020 as compared to 2019 despite a greater prevalence of persistent arrhythmia in 2020, indicating that healthcare resources were reutilized for COVID-19 care. As a result, fewer ablation procedures were performed, thereby negatively impacting the market. Thus, such circumstances greatly affected the market's growth rate throughout the initial pandemic phase. However, the market is anticipated to gain traction as several elective and cancer care procedures have resumed to pre-pandemic levels across the globe.

The factors propelling the studied market growth are the increasing prevalence of minimally invasive procedures, the growing burden of chronic diseases, and the senior population. For instance, as per the 2020 statistics by GLOBOCAN 2020, 19,292,789 people were diagnosed with cancer in 2020. According to the same source, the number of people with cancer is estimated to reach 30.2 million by 2040. Thus, increasing cancer prevalence indicates a rising need for effective minimally invasive surgical procedures for cancer, thereby driving the demand for radiofrequency ablation devices.

Additionally, strategic initiatives such as product launches, mergers, acquisitions, partnerships, and others will lead to lucrative market growth. For instance, in March 2022, Shijiazhuang Suin Instruments Co., Ltd. launched an RF signal generator, an instrument that's especially used to produce RF signals for carrier tests.

Furthermore, the rising research and development studies proving the efficacies of existing products in the market are expected to further contribute to the market's growth. For instance, the article "Next-generation catheter cuts AF ablation time," published in January 2022, evaluated the Biosense Webster's Qdot Micro catheter and demonstrated that it is a contact force-sensing radiofrequency ablation catheter with temperature-controlled ablation and 3D electroanatomical mapping integration. It incorporated advanced, high-energy ablation, improved temperature monitoring, optimized irrigation, and higher signal resolution, providing physicians with a simplified workflow that helps shorten procedure time. These advantages of radiofrequency ablation devices are expected to increase their adaptability, thereby driving the market growth. Moreover, in February 2022, Ramesh hospitals launched a modernized cardiac electrophysiology lab in Vijayawada, India, which will incorporate new therapies such as radio frequency ablation, pacemakers, automatic implantable cardiac defibrillators, and others. Thus, such initiatives will increase the demand for radio frequency devices, thereby driving the market growth.

Therefore, owing to the factors above, the studied market is expected to grow significantly during the study period. However, low awareness and availability of alternative treatment methods and high treatment costs are expected to hinder the market's growth during the forecast period.

Radiofrequency Ablation Devices Market Trends

Oncology Segment is Expected to Account for the Largest Market Share During the Forecast Period

The oncology segment holds a major share of the radiofrequency ablation devices market. The rising number of cancer cases around the world is adding to segmental growth. For example, a September 2021 World Health Organization (WHO) update stated that cancer resulted in approximately 10 million deaths worldwide. The most common cancers in 2020 (according to new cancer cases) were: breast cancer (2.26 million cases); lungs (2.21 million cases); colon and rectum (1.93 million cases); prostate (1.41 million patients); skin (non-melanoma) (1.20 million cases); and stomach (1.09 million cases). This increase in the number of cases over the years is majorly contributing to the increase in surgical therapies for efficient treatments, which in turn will propel the demand for ablation devices.

Furthermore, according to an article published by RadiologyInfo.org updated in February 2021, radiofrequency ablation (RFA), a minimally invasive treatment for cancer, employs an image-guided technique to apply heat to destroy cancer cells. RFA uses ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI) to guide a needle electrode into a cancerous tumor and passes high-frequency electrical currents through the electrode to ground pads placed on the body, thereby creating focused heat that destroys the cancer cells surrounding the electrode. The article also suggested that radio frequency and microwave ablations are the most commonly used ablation treatment methods for cancer therapy.

In addition, the growing investment in research and development will also increase the availability of radiofrequency ablation devices in the treatment of various types of cancer, thereby accelerating the segment's growth. For example, the study titled "Endoscopic Radiofrequency Ablation (RAF) Combined With Gemcitabine and S-1 in Patients for Unresectable Cholangiocarcinoma: A Randomized Open-Labeled Clinical Trial" was initiated in January 2020 by the First People's Hospital of Hangzhou to compare the efficacy and safety of RAF combined with Gemcitabine and S-1 in patients with unresectable cholangiocarcinoma. This study is expected to be completed by June 2022. Therefore, the positive results from such practices will spur the segment's growth.

Therefore, the studied segment is expected to project lucrative growth over the analysis period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same over the Forecast Period

The primary driving factors for the growth of the North American radiofrequency (RF) ablation devices market are the increasing prevalence of chronic diseases; increasing demand for minimally invasive surgeries; increasing product launches; and rising strategic initiatives by key market players. The United States is expected to hold a significant share in the studied market in the North American region during the forecast period. For instance, according to the estimates of the 2022 American Cancer Society, Inc., about 236,740 new cases of lung cancer will be diagnosed in the country in 2022. The same source also stated that 79,000 new cases and 13,920 deaths will be reported in 2022 from kidney cancer. Thus, the high burden of cancer is expected to boost the demand for ablation devices, thereby driving the market growth.

Moreover, strategic initiatives undertaken by the key market players, such as product launches, partnerships, new programs, mergers, and acquisitions, are likely to drive market growth. For instance, in February 2021, the Food and Drug Administration approved Medtronic's DiamondTemp irrigated ablation catheter in the RF cardiac ablation space, designed to treat patients with recurrent atrial fibrillation that has not responded to drug therapies.

Furthermore, in November 2020, Abbott launched the IonicRF Generator, which is expected to deliver a non-surgical, minimally invasive treatment for managing pain in the nervous system. The IonicRF Generator is a radiofrequency ablation device that uses heat to target specific nerves and block pain signals from reaching the brain. Thus, launching such products will expand the company's offerings and geographical footprint, driving market growth over the forecast period.

Thus, these aforementioned factors are anticipated to boost the growth of the market in the region over the coming years.

Radiofrequency Ablation Devices Market Competitor Analysis

The market is moderately competitive with major players dominating the market. The major players in the market are Avanos Medical Inc., Stryker, Abbott, Medtronic, Boston Scientific Corporation, and Others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Preference for Minimally Invasive Procedures
    • 4.2.2 Increasing Prevalence of Chronic Diseases
  • 4.3 Market Restraints
    • 4.3.1 Low awareness and availability of alternative treatment method
    • 4.3.2 High treatment cost
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Product Type
    • 5.1.1 Radiofrequency Generators
    • 5.1.2 Consumables
  • 5.2 By Application
    • 5.2.1 Oncology
    • 5.2.2 Cardiology and Cardiac Rhythm Management
    • 5.2.3 Gynecology
    • 5.2.4 Pain Management
    • 5.2.5 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Avanos Medical, Inc.
    • 6.1.2 Stryker
    • 6.1.3 Abbott
    • 6.1.4 Medtronic
    • 6.1.5 Boston Scientific Corporation
    • 6.1.6 Becton, Dickinson and Company (Venclose, Inc.)
    • 6.1.7 AngioDynamics, Inc.
    • 6.1.8 Hologic, Inc.
    • 6.1.9 AtriCure, Inc.
    • 6.1.10 Koninklijke Philips N.V.
    • 6.1.11 Smith+Nephew
    • 6.1.12 Baylis Medical Company, Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS